Brian McDonald

“You know, how fast is the business growing generally? And then on the acquisition, what's sort of the sort of gating factors or inhibiting factors to getting that closed at the end of the year?”

“I'd appreciate all the color on the call here with the strategic pivot, but Andrew, I'm curious, of the categories you've talked about a lot here, weight loss, labs, testosterone, menopause, are these primarily sort of US-based, domestic-based drivers of the business today?”

“I apologize if it's been asked already, but on the pathway acquisition, just curious how you're planning to sort of integrate that into Doximity. Do you expect it to be sort of an extension of the core news feed?”

“As we look at the GLP-1 business, you talked about personalized and commercial. Can you give us a sense of what the rough mix is across that? And then as we get past Q1 here, is there any risk, whether it be from a legal or regulatory perspective, on continuing to offer the personalized version in your view?”